Navigation Links
Silence Therapeutics Additional Listing
Date:12/20/2011

LONDON, December 20, 2011 /PRNewswire/ --

Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") a leading global RNA interference (RNAi) therapeutics company, today announces that application has been sought for 530,000 new ordinary shares of 1 pence each ("Ordinary Shares") to be admitted to trading on AIM. The new Ordinary Shares are being issued in accordance with a contractual agreement with Dr. Philip Haworth, former Chief Executive Officer of Silence.

It is expected that dealings in the new Ordinary Shares, which will rank pari passu in all respects with the existing issued share capital of the Company, will commence on 21 December 2011.

Notes for editors

About Silence Therapeutics plc (http://www.silence-therapeutics.com)

Silence Therapeutics plc (AIM: SLN) is a leading biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases. Silence offers one of the most comprehensive short interfering RNA (siRNA) therapeutic platforms available today based on a strong intellectual property portfolio and large clinical safety database. Silence's clinical siRNA product pipeline is one of the broadest in the industry.

The Company possesses multiple proprietary siRNA delivery technology platforms including AtuPLEX™, DACC and DBTC. AtuPLEX enables the broad functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake. The DACC delivery system allows functional delivery of siRNA molecules selectively to the lung endo-thelium with a long duration of target mRNA and protein knock-down. The DBTC delivery system enables functional delivery of siRNA molecules selectively to liver cells including hepatocytes.

Additionally, the Company has a platform of novel siRNA molecules based around its AtuRNAi chemical modification technology, which provides a number of advantages over conventional siRNA molecules. Silence's unique RNAi assets also include structural features for RNAi molecules and specific design rules for increased potency and reduced off-target effects of siRNA sequences.

The Company's lead internal drug candidate is Atu027, a liposomal formulation in clinical development for systemic cancer indications and one of the most clinically advanced RNAi therapeutic candidates in the area of oncology. Atu027 incorporates two of the Company's technologies, AtuRNAi and AtuPLEX™. Silence is currently conducting an open-label, single-centre, dose-escalation Phase I study with Atu027 in patients with advanced solid tumors involving single, as well as repeated, intravenous administration. Encouraging interim safety and pharmacokinetic data were presented at the American Society of Clinical Oncology Annual Meeting in June 2011. The study is expected to be completed in the first half of 2012.

The Company's RNAi therapeutic platform has received key validation through multiple partnerships with pharmaceutical companies including AstraZeneca, Dainippon Sumitomo, Pfizer/Quark, and Novartis/Quark. Silence is actively pursuing the establishment of additional partnerships. Silence Therapeutics has operations in both Berlin and London.

For further information, please contact:

Silence Therapeutics
Thomas Christély/Max Herrmann
+49-30-9489-2800/+44-20-7491-6520
t.christely@silence-therapeutics.com
m.herrmann@silence-therapeutics.com

M:Communications (Europe)
Peter Laing / Emma Thompson / Claire Dickinson
+44-20-7920-2345 / +44-20-7920-2342
healthcare@mcomgroup.com

Singer Capital Markets
Shaun Dobson/Claes Spång
+44-20-3205-7500
shaun.dobson@singercm.com
claes.spang@singercm.com    



'/>"/>
SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
2. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
3. Silence Therapeutics Appoints New Vice President of Research
4. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
5. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
6. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
7. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
8. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
9. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
10. Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics
11. Silence Therapeutics Provides Corporate and Development Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... March 21, 2017 , ... Premier executive recruitment firm, ... Science Search Firm by Hunt Scanlon Media. , Hunt Scanlon Media is ... most widely referenced global news source in the human capital sector. , “It is ...
(Date:3/22/2017)... ... March 21, 2017 , ... Benchworks CEO Thad L. Bench ... on March 23-24 in San Diego. The event is a gathering of executive ... , Benchworks Vice President Christian Meyer will also participate in the forum. Participants will ...
(Date:3/22/2017)... , ... March 21, 2017 ... ... WMFTG ) has unveiled its innovative Quantum peristaltic pump with patented ReNu ... Quantum sets the new standard for high-pressure feed pumps in SU tangential ...
(Date:3/22/2017)... , ... March 22, 2017 , ... March 22, 2017...Council ... for another green revolution, one that utilizes technological innovation in smart, sustainable ways. Humans ... of life such as aesthetics and environmental stability. This paper is the first in ...
Breaking Biology Technology:
(Date:3/2/2017)... March 2, 2017 Summary This report ... and its partnering interests and activities since 2010. ... Read the full ... Alliance since 2010 report provides an in-depth insight into the ... companies. On demand company reports are prepared upon ...
(Date:3/2/2017)... MELBOURNE, Australia , March 2, 2017 ... Therapeutics Ltd (ASX: CYP), has signed an agreement ... researchers from the Monash Biomedicine Discovery Institute and Department ... , to conduct a further preclinical study to support ... the treatment of asthma.  Asthma is ...
(Date:2/28/2017)... Germany , February 28, 2017 News ... ... Amsterdam from 14 to 16 March, Materna ... destination, and show how seamless travel is a real benefit for ... has added biometrics to their passenger touch point solutions to take ...
Breaking Biology News(10 mins):